As at 30th November 2018, the number of ordinary shares in issue was 61,626,327.
As at 30th November 2018, the Company has been notified of the following interests in 3% or more of the issued ordinary share capital of the Company:
|No of Ordinary Shares||%|
|Balderton Capital III, LP1||6,813,196||11.06|
|Genostics Company Ltd2||6,410,256||10.40|
|FIL Investment International||3,119,981||5.06|
|University of Nottingham||2,244,527||3.64|
|Professor John Robertson3||2,236,923||3.63|
|Aviva Investors Global Services Limited||2,213,485||3.59|
1 Mr Bunting is a partner of Balderton Capital (UK) LLP the investment adviser to Balderton Capital Partners III, LP.
2 Cheung To is a shareholder and director of Genostics Company Ltd.
3 644,550 shares are jointly owned with the Employee Benefit Trust.
|No of Shares||No of Share Options||No of Warrants|
Shares not in Public Hands
In accordance with the definition in the AIM Rules for Companies and insofar as it is aware, as at 6th December 2018, 40.51% of the Company’s AIM securities was not in public hands.
Restrictions on Transfer of Aim Securities
There are no restrictions on the transfer of securities.
UK City Code on Takeovers and Mergers
Ocimmune Holdings Plc is subject to the UK City Code on Takeovers and Mergers.
Details of Other Exchanges or Trading Platforms
Other than AIM, the Company’s shares are not admitted to or traded on any other exchanges or trading platforms.